Rigel Pharmaceuticals
RIGL
91 hedge funds and large institutions have $85.4M invested in Rigel Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 39 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
52.85% more ownership
Funds ownership: 6.33% → 59.18% (+53%)
16% more call options, than puts
Call options by funds: $4.28M | Put options by funds: $3.68M
22% less funds holding
Funds holding: 117 → 91 (-26)
48% less capital invested
Capital invested by funds: $164M → $85.4M (-$78.9M)
67% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.25M |
| 3 |
Jane Street
New York
|
+$1.06M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$941K |
| 5 |
AC
Armistice Capital
New York
|
+$921K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.77M |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
-$2.96M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.95M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$2.37M |
| 5 |
Millennium Management
New York
|
-$1.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
126
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$6.49K | -438 | Closed |
|
127
Lazard Asset Management
New York
| – | -$4K | -328 | Closed |
|
|
CA
128
Continuum Advisory
Eagle,
Idaho
| – | -$596 | -58 | Closed |
|
|
LWCFA
129
Loring Wolcott & Coolidge Fiduciary Advisors
Boston,
Massachusetts
| – | -$31 | -3 | Closed |
|
130
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$450 | +43 | New |
|
RIGL Hedge Fund Activity: Q2 2024 in Review
91 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2024, worth a combined $85.4M — down 48% from $164M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of RIGL and 13 opened new positions — a net loss of 26 holders — while 25 trimmed existing stakes and 39 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.1M. The largest seller was Nuveen, exiting entirely with an estimated $4.77M sold.
- 91 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2024, down from 117 in Q1 2024.
- Funds reported $85.4M of Rigel Pharmaceuticals stock for Q2 2024, down 48% quarter-over-quarter.
- 13 funds opened new Rigel Pharmaceuticals positions in Q2 2024 and 39 closed out, a net change of -26 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2024 was Stonepine Capital Management, an estimated $2.1M added.
- The largest Rigel Pharmaceuticals seller in Q2 2024 was Nuveen, an estimated $4.77M sold.
Based on aggregated 13F filings for Q2 2024.